By HealthDay Staff HealthDay Reporter
FRIDAY, Oct. 2, 2026 (HealthDay News) — More women are now being prescribed GLP-1 medications like Ozempic and Zepbound after giving birth.
A new study finds GLP-1 use among new mothers jumped from less than 0.1% in 2018 to nearly 2% in early 2025 — a 24-fold increase.
Researchers looked at insurance claims covering more than 1 million births over seven years.
The fastest increase in use was among women diagnosed as overweight or obese — up from 0.4% in 2021 to 3.9% in early 2025.
They now account for about 40% of new postpartum prescriptions, according to the results.
Overall, women with type 2 diabetes had the highest rate, with nearly 1 in 6 starting a GLP-1.
Patients are advised to stop using GLP-1s during pregnancy.
After giving birth, most women didn't start right away — nearly 62% waited three to six months.
The lead author said the postpartum period is a critical window for addressing metabolic risk after pregnancy.
"Because evidence on GLP-1 exposure during breastfeeding remains limited, rising postpartum initiation warrants further study," said lead author Sih-Ting Cai of the USC Schaeffer Center for Health Policy & Economics.
This new research could not determine whether the women taking GLP-1s were breastfeeding.
The study was published Oct. 1 in the Journal of the American Medical Association.
More information
The Cleveland Clinic has more on GLP-1 medications.
SOURCE: HealthDay TV, Oct. 2, 2026
Back
The news stories provided in Health News and our Health-E News Newsletter are a service of the nationally syndicated HealthDay® news and information company. Stories refer to national trends and breaking health news, and are not necessarily indicative of or always supported by our facility and providers. This information is provided for informational and educational purposes only, and is not intended to be a substitute for medical advice, diagnosis, or treatment.
